[go: up one dir, main page]

BG64004B1 - Производни на хинолина като тахикинин nк долу 3 рецепторни антагонисти - Google Patents

Производни на хинолина като тахикинин nк долу 3 рецепторни антагонисти Download PDF

Info

Publication number
BG64004B1
BG64004B1 BG101008A BG10100896A BG64004B1 BG 64004 B1 BG64004 B1 BG 64004B1 BG 101008 A BG101008 A BG 101008A BG 10100896 A BG10100896 A BG 10100896A BG 64004 B1 BG64004 B1 BG 64004B1
Authority
BG
Bulgaria
Prior art keywords
carboxamide
phenylquinoline
benzyl
methoxycarbonyl
formula
Prior art date
Application number
BG101008A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101008A (en
Inventor
Carlo Farina
Giuseppe Giardina
Mario Grugni
Luca Raveglia
Original Assignee
Smithkline Beecham S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT94MI001099A external-priority patent/ITMI941099A1/it
Priority claimed from ITMI950494 external-priority patent/IT1293558B1/it
Application filed by Smithkline Beecham S.P.A. filed Critical Smithkline Beecham S.P.A.
Publication of BG101008A publication Critical patent/BG101008A/xx
Publication of BG64004B1 publication Critical patent/BG64004B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ceramic Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Structural Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
BG101008A 1994-05-27 1996-11-25 Производни на хинолина като тахикинин nк долу 3 рецепторни антагонисти BG64004B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT94MI001099A ITMI941099A1 (it) 1994-05-27 1994-05-27 Derivati chinolinici
ITMI950494 IT1293558B1 (it) 1995-03-14 1995-03-14 Derivati chinolinici
PCT/EP1995/002000 WO1995032948A1 (en) 1994-05-27 1995-05-23 Quinoline derivatives as tachykinin nk3 receptor antagonists

Publications (2)

Publication Number Publication Date
BG101008A BG101008A (en) 1997-08-29
BG64004B1 true BG64004B1 (bg) 2003-09-30

Family

ID=26331143

Family Applications (2)

Application Number Title Priority Date Filing Date
BG101008A BG64004B1 (bg) 1994-05-27 1996-11-25 Производни на хинолина като тахикинин nк долу 3 рецепторни антагонисти
BG103181A BG103181A (bg) 1994-05-27 1999-02-16 Използване на непептидни nk3 антагонисти за лечение на кожни заболявания и сърбеж

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG103181A BG103181A (bg) 1994-05-27 1999-02-16 Използване на непептидни nk3 антагонисти за лечение на кожни заболявания и сърбеж

Country Status (34)

Country Link
US (5) US5811553A (no)
EP (2) EP0940391B1 (no)
JP (5) JP3664492B2 (no)
KR (1) KR100316571B1 (no)
CN (3) CN1092642C (no)
AP (1) AP578A (no)
AR (1) AR037069A2 (no)
AT (2) ATE273959T1 (no)
AU (1) AU699319B2 (no)
BG (2) BG64004B1 (no)
BR (1) BR9507788A (no)
CA (1) CA2191352C (no)
CZ (1) CZ291476B6 (no)
DE (2) DE69533408T2 (no)
DK (1) DK0804419T3 (no)
DZ (1) DZ1889A1 (no)
ES (2) ES2227769T3 (no)
FI (2) FI115052B (no)
HU (1) HU226535B1 (no)
IL (1) IL113844A (no)
MA (1) MA23560A1 (no)
MX (1) MX9605903A (no)
MY (1) MY129596A (no)
NO (2) NO307783B1 (no)
NZ (1) NZ287442A (no)
OA (1) OA10592A (no)
PL (2) PL186665B1 (no)
PT (2) PT940391E (no)
RO (1) RO114445B1 (no)
SA (1) SA95160290B1 (no)
SK (2) SK282721B6 (no)
TW (2) TW427977B (no)
UA (1) UA51623C2 (no)
WO (1) WO1995032948A1 (no)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2227769T3 (es) * 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
SK66798A3 (en) * 1995-11-24 1999-01-11 Smithkline Beecham Spa Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU757836B2 (en) * 1995-11-24 2003-03-06 Smithkline Beecham Spa Quinoline derivatives
DE69824582T2 (de) * 1997-03-14 2005-07-07 Smithkline Beecham Corp. Neuartige Chinolin- und Naphthalincarboxamide, pharmazeutische Zusammensetzungen und Verfahren zum Inhibieren von Calpain
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20010012846A1 (en) * 1997-05-23 2001-08-09 Glardina Giuseppe Arnaldo Maria Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
CN1264378A (zh) * 1997-05-23 2000-08-23 史密丝克莱恩比彻姆股份公司 作为nk－2和nk－3受体拮抗剂的喹啉－4－甲酰胺衍生物
EP1652840A3 (en) * 1997-09-17 2006-05-17 Smithkline Beecham Corporation (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
US6780875B2 (en) * 1998-11-20 2004-08-24 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
EP1131295A1 (en) * 1998-11-20 2001-09-12 Smithkline Beecham S.p.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
JP2002535274A (ja) * 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 抗アンドロゲン剤および疾病の治療方法
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
EP1165542B1 (en) 1999-03-29 2003-08-20 Neurogen Corporation 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AU2001276556A1 (en) * 2000-08-11 2002-02-25 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
JP2004525184A (ja) * 2001-04-11 2004-08-19 グラクソスミスクライン・ソシエタ・ペル・アチオニ Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしての３−置換キノリン−４−カルボキサミド誘導体
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
EP1541149A1 (en) * 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
GB0228287D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228288D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
RU2229475C1 (ru) * 2003-03-06 2004-05-27 ООО "Исследовательский институт химического разнообразия 6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
CA2549956C (en) 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
CA2555133A1 (en) 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
EP1729751A1 (en) * 2004-03-25 2006-12-13 Smithkline Beecham Corporation Use of an nk3 antagonist for the treatment of bipolar disorders
BRPI0508111A (pt) * 2004-03-30 2007-07-17 Smithkline Beecham Corp composições farmacêuticas secas por aspersão
US7495103B2 (en) 2004-06-24 2009-02-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
GB0417559D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0417560D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425075D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425076D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
CN101189211A (zh) * 2005-06-03 2008-05-28 阿斯利康(瑞典)有限公司 作为nk3拮抗剂的喹啉衍生物
WO2006137789A1 (en) * 2005-06-23 2006-12-28 Astrazeneca Ab Quinoline 3 -sulfonate esters as NK3 receptor modulators
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504572A (ja) * 2005-08-02 2009-02-05 スミスクライン・ビーチャム・コーポレイション キノリン誘導体の合成方法
US20080280949A1 (en) * 2005-08-11 2008-11-13 Astrazeneca Ab Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
CN101287723A (zh) * 2005-08-11 2008-10-15 阿斯利康(瑞典)有限公司 作为nk3受体调节剂的酰胺烷基吡啶基喹啉
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
JP2009508944A (ja) * 2005-09-21 2009-03-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体リガンドとしてのｎ−オキソ複素環及びｎ−オキソ−アルキルキノリン−４−カルボキシアミド類
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2009524656A (ja) * 2006-01-27 2009-07-02 アストラゼネカ・アクチエボラーグ アミド置換キノリン
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
MX2009010059A (es) 2007-03-22 2009-10-12 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8614326B2 (en) * 2007-08-22 2013-12-24 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
WO2009049791A2 (en) * 2007-10-15 2009-04-23 F. Hoffmann-La Roche Ag Radiolabeled nk3 receptor antagonist
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
ES2401059T3 (es) * 2008-06-23 2013-04-16 H. Lundbeck A/S Derivados de isoquinolinona como antagonistas de NK3
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
CA2739946A1 (en) 2008-10-20 2010-04-29 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
SMT201700593T1 (it) 2009-03-20 2018-03-08 Vertex Pharma Procedimento per preparare modulatori di regolatore di conduttanza transmembrana di fibrosi cistica
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US9346814B2 (en) 2012-01-17 2016-05-24 Universiteit Antwerp FAP inhibitors
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CN102702099A (zh) * 2012-06-21 2012-10-03 江苏恩华药业股份有限公司 (s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法
CA2909752A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
EP3915560A1 (en) 2014-06-25 2021-12-01 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
WO2016004035A1 (en) * 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases
CN107074773A (zh) 2014-09-09 2017-08-18 拜耳制药股份公司 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CA2979926A1 (en) 2015-03-18 2016-09-22 Bayer Pharma Aktiengesellschaft Substituted n-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
KR102704783B1 (ko) * 2015-05-18 2024-09-10 칸디 테라퓨틱스 리미티드 성-호르몬 의존성 질환의 치료를 위한 이중 nk-1/nk-3 수용체 길항제
BR112018007021B1 (pt) * 2015-10-06 2024-01-09 Proteostasis Therapeutics, Inc Composto, composição compreendendo os ditos compostos e uso dos mesmos para tratar fibrose cística
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
JP7107963B2 (ja) * 2017-04-10 2022-07-27 バイエル・アクチエンゲゼルシヤフト 置換されたｎ－アリールエチル－２－アリールキノリン－４－カルボキサミド類及びそれの使用
US11458129B2 (en) 2017-11-02 2022-10-04 California Institute Of Technology Neurokinin antagonists and uses thereof
EP3881843A4 (en) * 2018-11-15 2022-08-03 Kyushu University, National University Corporation PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1560489A (en) * 1976-05-21 1980-02-06 Fisons Ltd Pharmaceutical compositions
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
DE3905339A1 (de) * 1989-02-22 1990-09-06 Basf Ag Chinolin-4-carbonsaeurederivate und deren verwendung
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5037835A (en) * 1989-10-24 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
DE69126058T2 (de) * 1990-03-26 1997-09-25 Matsushita Electric Ind Co Ltd Lichtempfindliches Material für Elektrophotographie
EP0585913B1 (en) * 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
ES2227769T3 (es) 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists

Also Published As

Publication number Publication date
PL186075B1 (pl) 2003-10-31
PT940391E (pt) 2004-12-31
SK4799A3 (en) 1999-06-11
DZ1889A1 (fr) 2002-02-17
CZ291476B6 (cs) 2003-03-12
CN1092642C (zh) 2002-10-16
US20050096316A1 (en) 2005-05-05
DK0804419T3 (da) 2003-11-24
JP2002179594A (ja) 2002-06-26
WO1995032948A1 (en) 1995-12-07
OA10592A (en) 2002-08-27
PL186665B1 (pl) 2004-02-27
SK151496A3 (en) 1997-07-09
CN1428145A (zh) 2003-07-09
CZ347096A3 (en) 1997-10-15
EP0940391B1 (en) 2004-08-18
US20030236281A1 (en) 2003-12-25
PL317381A1 (en) 1997-04-01
NO307783B1 (no) 2000-05-29
SK282721B6 (sk) 2002-11-06
FI990268L (fi) 1999-02-10
TW427977B (en) 2001-04-01
US20060160846A1 (en) 2006-07-20
DE69531458D1 (de) 2003-09-11
DE69531458T2 (de) 2004-08-05
AU2616495A (en) 1995-12-21
ATE273959T1 (de) 2004-09-15
AU699319B2 (en) 1998-12-03
NZ287442A (en) 1998-05-27
US6608083B1 (en) 2003-08-19
FI964712L (fi) 1997-01-23
EP0940391A2 (en) 1999-09-08
ATE246677T1 (de) 2003-08-15
HU226535B1 (en) 2009-03-30
US5811553A (en) 1998-09-22
EP0940391A3 (en) 1999-11-10
HU9603262D0 (en) 1997-01-28
MA23560A1 (fr) 1995-12-31
FI964712A0 (fi) 1996-11-26
BG103181A (bg) 1999-09-30
JP2005068155A (ja) 2005-03-17
TW533199B (en) 2003-05-21
FI115052B (fi) 2005-02-28
MY129596A (en) 2007-04-30
CN1156451A (zh) 1997-08-06
DE69533408T2 (de) 2005-09-08
JP2007126475A (ja) 2007-05-24
NO965036D0 (no) 1996-11-26
SA95160290B1 (ar) 2006-06-21
HK1024469A1 (en) 2000-10-13
FI119721B (fi) 2009-02-27
JPH10500697A (ja) 1998-01-20
NO991813L (no) 1997-01-24
BG101008A (en) 1997-08-29
HUT76286A (en) 1997-07-28
AP578A (en) 1997-03-26
KR100316571B1 (ko) 2002-05-30
NO326714B1 (no) 2009-02-02
NO991813D0 (no) 1999-04-16
DE69533408D1 (de) 2004-09-23
HK1003884A1 (en) 1998-11-13
JP3664492B2 (ja) 2005-06-29
PT804419E (pt) 2003-12-31
SA95160290A (ar) 2005-12-03
EP0804419A1 (en) 1997-11-05
SK282722B6 (sk) 2002-11-06
JP2000026314A (ja) 2000-01-25
MX9605903A (es) 1998-08-30
CN1276211A (zh) 2000-12-13
UA51623C2 (uk) 2002-12-16
CA2191352A1 (en) 1995-12-07
IL113844A0 (en) 1995-08-31
NO965036L (no) 1997-01-24
AP9500745A0 (en) 1995-07-31
RO114445B1 (ro) 1999-04-30
BR9507788A (pt) 1997-09-23
IL113844A (en) 2005-05-17
ES2227769T3 (es) 2005-04-01
US7482458B2 (en) 2009-01-27
AR037069A2 (es) 2004-10-20
ES2204952T3 (es) 2004-05-01
CA2191352C (en) 2001-01-30
EP0804419B1 (en) 2003-08-06
FI990268A0 (fi) 1999-02-10

Similar Documents

Publication Publication Date Title
BG64004B1 (bg) Производни на хинолина като тахикинин nк долу 3 рецепторни антагонисти
US6743804B2 (en) Quinoline derivatives as NK3 antagonists
US6277862B1 (en) Quinoline derivatives
SK159299A3 (en) Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
US20020156097A1 (en) Salts of quinoline derivatives as NK3 antagonists
RU2155754C2 (ru) Производные хинолина как антагонисты nk3-рецептора тахикинина
CA2257662C (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
HK1024469B (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
PL188872B1 (pl) Pochodne chinoliny jako antagoniści receptorów NK3 tachykininy
HK1003884B (en) Quinoline derivatives as tachykinin nk3 receptor antagonists